Gastrointestinal adverse events · women with polycystic ovary syndrome
Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Ovulation rate · women with polycystic ovary syndrome
Metformin may leads to higher ovulation rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Menstrual blood loss: mean loss · women with heavy menstrual bleeding
1 finding from 1 review
Menstrual blood loss: improvement rates · women with heavy menstrual bleeding
Antifibrinolytics probably leads to higher menstrual blood loss: improvement rates compared with no treatment or placebo (moderate certainty).
1 finding from 1 review
Adverse events (any) · women with heavy menstrual bleeding
Antifibrinolytics showed no clear difference in adverse events (any) compared with no treatment or placebo (low certainty).
1 finding from 1 review
Thromboembolic events · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐reported pain (dysmenorrhoea) at the end of treatment (continuous data): dysmenorrhoea at 6 months' · women with endometriosis
2 findings from 1 review
Self‐reported pain: menstrual pain reduction from baseline to end of treatment · women with endometriosis
1 finding from 1 review
Live birth · women undergoing fertility treatment
Vasodilator showed no clear difference in live birth compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Vasodilator side effects · women undergoing fertility treatment
Vasodilator probably leads to higher vasodilator side effects compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Clinical pregnancy · women undergoing fertility treatment
Vasodilator may leads to higher clinical pregnancy compared with placebo or no treatment (low certainty).
1 finding from 1 review
Thickened endometrium · women undergoing fertility treatment
1 finding from 1 review
Multiple gestation or birth · women undergoing fertility treatment
Vasodilator showed no clear difference in multiple gestation or birth compared with placebo or no treatment (low certainty).
1 finding from 1 review
Miscarriage · women undergoing fertility treatment
Vasodilator showed no clear difference in spontaneous miscarriage compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ectopic pregnancy · women undergoing fertility treatment
Vasodilator showed no clear difference in ectopic pregnancy compared with placebo or no treatment (low certainty).
1 finding from 1 review
Live birth · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes live birth compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
Myo‐inositol showed no clear difference in adverse event ‐ multiple pregnancy compared with placebo, no/standard treatment (low certainty).
1 finding from 1 review
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found